To synthesize data from four observational studies to evaluate the effectiveness and safety of tildrakizumab in diverse patient populations with moderate-to-severe plaque psoriasis, addressing gaps in existing literature regarding specific subgroups.
Key Findings:
Tildrakizumab demonstrated positive outcomes across various parameters (PASI, BSA, PGA, DLQI) at week 28, with statistically significant improvements noted in special populations, including those with high body weight and older patients.
Interpretation:
The results support the reliability of tildrakizumab treatment across diverse patient profiles and highlight its positive impact on quality of life for individuals with plaque psoriasis, suggesting a need for broader adoption in clinical practice.
Limitations:
Observational studies may have inherent biases compared to randomized controlled trials, including selection bias and confounding factors. The studies were conducted in Germany, which may limit generalizability to other populations.
Conclusion:
Tildrakizumab is effective and safe for treating moderate-to-severe plaque psoriasis in real-world settings, particularly in diverse patient groups, emphasizing the importance of real-world evidence in treatment decisions.
